22 Comments
 

Yes, Aebersold and Sorenson (NY RX) left to ROTH (probably poached by Andrew Yearley, who himself left LAZ ~a year ago). At this point, only the legacy is really left at LAZ RX.

They are definitely not tier 1 (PJT RSSG, EVR RX) or even tier 2 (HL RX, MOE). They are probably somewhere with PWP, GHL, or GUGG (which is still great obviously, but considering that LAZ RX was often touted in the past as a tier 1 shop (alongside BX/PJT), it's a big fall)  

 

Exits are still good from what I hear (TPG, Apollo, Searchlight...). Talent though is weak, especially at the senior level. Overall, not the place to be. It's amazing how this group has fallen over the last 3-5 years - Used to dominate the RX scene next to PJT/BX. Now it's below the likes of MOE and EVR RX, probably in line PWP

 

have heard culture and WFH policy kinda sucks ass compared to rest of the Laz groups.

 

Take the credit shop. Worked across the table from Lazard and it does not look good. Other RX firms have much better deal flow and culture.

 
Most Helpful

Lot of misconceptions here, am pretty familiar with the group / situation. All the MDs who have left for Roths were underperforming / were pushed out, would not consider any of them to be meaningful. Think this is part of a firm-wide push to push out bad MDs and improve talent (if I recall they also hired a couple solid names in the distressed space to replace them). Couple news articles about this online

Have heard the nyc culture is alright, especially since those MDs have been pushed out. Believe exits are still quite strong, like someone else mentioned. Don’t know much about their Chicago office but think it’s pretty relaxed

 

Dunno man, the MDs they brought over aren't exactly stellar and frankly, when ~50% of your MD count leaves in a year it doesn't seem to be involuntary but rather an evacuation of a sinking ship

 

Agree with this...they had some major MDs leave in a mass exodus then the two MDs they brought in seem to be more creditor oriented. It's like...sure...we can't bring in any debtor mandates anymore because our platform has declined significantly so let's build out a creditor and UCC practice? I mean look at their background here: https://www.lazard.com/news-announcements/lazard-welcomes-two-new-manag…;

It will take a lot of time for Laz to be an industry leading Rx platform again, especially when other "T 2" shops are winning very solid mandates...

 

Lazard Rx is doing just fine… know the group directly. Def not pulling like 80% all debtor work any more, but still a very strong group.

 

At a different LAZ group, but the RX group is known to be a shitshow. Terrible culture with a shaky base. Exits are fine for now

 

Quos et quidem voluptatem sit qui ut. Expedita fugiat eaque at ipsum et. Dolores autem possimus enim a tenetur.

Tempore molestias voluptatibus atque ab reiciendis hic sint voluptas. Ad voluptas dolorem sit sed aspernatur recusandae. At voluptatem et doloremque nostrum ullam autem saepe. Sit aut iure blanditiis ut molestiae hic veritatis esse. Necessitatibus consequatur officia recusandae repudiandae. Rerum esse ut beatae exercitationem sed amet omnis.

Laudantium enim qui harum sunt commodi. Expedita in dolorem eius voluptatem delectus. Vitae est voluptatibus mollitia voluptatem sed.

Voluptas ut nihil dignissimos corrupti ducimus doloribus. Modi ut fuga perferendis modi molestiae ut nam rerum. Sequi libero nostrum architecto vero distinctio corporis quod omnis.

 
Funniest

Vel sit sapiente nemo praesentium aut ut. Aliquam est eum magni impedit. Enim ea temporibus officia temporibus ipsa totam et magni.

At eius culpa quas repellat officia facilis reprehenderit. Minima voluptatem voluptate esse qui quo ea ab sint. Voluptatum autem tenetur autem et et aut. Perspiciatis aut dolor sunt optio. Nostrum placeat totam itaque.

Eveniet iusto perspiciatis corporis. Dolores reprehenderit voluptas quo eum optio soluta. Aut voluptatem repudiandae dolorem est voluptas voluptatem.

Nihil ut voluptas quasi in excepturi libero. Assumenda provident porro quam fuga molestiae quo. Explicabo doloribus adipisci enim excepturi facilis qui necessitatibus. Rem rerum aliquam error dolor aut. Aut autem quia et cumque. Ratione repudiandae alias distinctio voluptatem sit dolores.

Career Advancement Opportunities

July 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.3%
  • Guggenheim Partners 01 97.7%
  • Morgan Stanley 07 97.1%

Overall Employee Satisfaction

July 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Evercore No 98.9%
  • Morgan Stanley 01 98.3%
  • BMO Capital Markets 13 97.7%
  • Banco Santander 01 97.1%

Professional Growth Opportunities

July 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 06 98.3%
  • Goldman Sachs 01 97.7%
  • JPMorgan 01 97.1%

Total Avg Compensation

July 2026 Investment Banking

  • Vice President (16) $429
  • Associates (46) $258
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (14) $159
  • 1st Year Analyst (80) $150
  • Intern/Summer Analyst (73) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
kanon's picture
kanon
99.0
3
Secyh62's picture
Secyh62
99.0
4
BankonBanking's picture
BankonBanking
99.0
5
GameTheory's picture
GameTheory
98.9
6
Betsy Massar's picture
Betsy Massar
98.9
7
DrApeman's picture
DrApeman
98.9
8
dosk17's picture
dosk17
98.9
9
CompBanker's picture
CompBanker
98.9
10
Linda Abraham's picture
Linda Abraham
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”